Computer Assisted Drug Design of Therapeutic Hydroxyarylmethane Derivatives
Aurin Biotech has demonstrated that aurintricarboxylic acid (ATA) and related hydroxyarylmethane derivatives are potent inhibitors of the terminal complement cascade. The complement cascade is a potent initiator and enhancer of the inflammatory response which leads to pathophysiological consequences including cell death and tissue remodeling in a range of chronic diseases. This project uses two distinct but complementary arms; 1) synthetic chemistry of novel hydroxyarylmethane derivatives and 2) computer assisted drug design (CADD) to design new chemical entities in silico. Both avenues of investigation will be informed by key medicinal chemistry and preclinical analytical analysis to supplement and extend the company’s investigational drug candidate pipeline.
Voir la description complète du projetTara Klassen;David Grierson
Aurin Biotech Inc
Life Sciences
Professional, scientific and technical services
The University of British Columbia
Accelerate
